Product: Ret Antibody
Catalog: AF6120
Description: Rabbit polyclonal antibody to Ret
Application: WB IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Sheep, Rabbit, Dog, Xenopus
Mol.Wt.: 175kDa; 124kD(Calculated).
Uniprot: P07949
RRID: AB_2835004

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:2000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Pig(100%), Zebrafish(100%), Bovine(100%), Sheep(100%), Rabbit(100%), Dog(100%), Xenopus(100%)
Ret Antibody detects endogenous levels of total Ret.
Cite Format: Affinity Biosciences Cat# AF6120, RRID:AB_2835004.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


C ret; Cadherin family member 12; Cadherin related family member 16; CDHF 12; CDHF12; CDHR16; ELKS Fusion gene; HSCR 1; HSCR1; Hydroxyaryl protein kinase; MEN2A; MEN2B; MTC 1; MTC1; Multiple endocrine neoplasia and medullary thyroid carcinoma 1; Oncogene RET; Proto oncogene tyrosine protein kinase receptor ret; Proto-oncogene c-Ret; Proto-oncogene tyrosine-protein kinase receptor ret; PTC; RET; RET ELE1; Ret Proto oncogene; RET transforming sequence; RET_HUMAN; RET51; RET9; tyrosine-protein kinase receptor ret;


This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement.



Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P07949 As Substrate

Site PTM Type Enzyme
N151 N-Glycosylation
S159 Phosphorylation
T350 Phosphorylation
T675 Phosphorylation P17252 (PRKCA)
S686 Phosphorylation
Y687 Phosphorylation P07949 (RET)
S688 Phosphorylation
S696 Phosphorylation P17612 (PRKACA)
S699 Phosphorylation
S705 Phosphorylation
Y752 Phosphorylation
T754 Phosphorylation
Y791 Phosphorylation
Y806 Phosphorylation P07949 (RET)
Y809 Phosphorylation P07949 (RET)
Y826 Phosphorylation P07949 (RET)
Y864 Phosphorylation
S891 Phosphorylation
Y900 Phosphorylation P07949 (RET)
S904 Phosphorylation
Y905 Phosphorylation Q05397 (PTK2) , P07949 (RET) , P12931 (SRC)
S909 Phosphorylation
Y928 Phosphorylation
Y952 Phosphorylation
Y981 Phosphorylation P07949 (RET)
Y1015 Phosphorylation P07949 (RET)
Y1029 Phosphorylation P07949 (RET)
K1060 Ubiquitination
Y1062 Phosphorylation P07949 (RET)
S1065 Phosphorylation
Y1090 Phosphorylation P07949 (RET)
Y1096 Phosphorylation P07949 (RET)
K1107 Ubiquitination
T1111 Phosphorylation
S1114 Phosphorylation

PTMs - P07949 As Enzyme

Substrate Site Source
O15530 (PDPK1) Y9 Uniprot
P07949-1 (RET) Y687 Uniprot
P07949 (RET) Y806 Uniprot
P07949 (RET) Y809 Uniprot
P07949 (RET) Y826 Uniprot
P07949-2 (RET) Y900 Uniprot
P07949-2 (RET) Y905 Uniprot
P07949-2 (RET) Y981 Uniprot
P07949-1 (RET) Y1015 Uniprot
P07949-2 (RET) Y1029 Uniprot
P07949 (RET) Y1062 Uniprot
P07949 (RET) Y1090 Uniprot
P07949 (RET) Y1096 Uniprot
P18848 (ATF4) T107 Uniprot
P18848 (ATF4) T114 Uniprot
P18848 (ATF4) T115 Uniprot
P18848 (ATF4) T119 Uniprot
P19174 (PLCG1) Y783 Uniprot
P27361 (MAPK3) Y204 Uniprot
P27986 (PIK3R1) Y203 Uniprot
P28482-1 (MAPK1) Y187 Uniprot
P31749 (AKT1) Y315 Uniprot
P35222 (CTNNB1) Y654 Uniprot
P45983 (MAPK8) Y185 Uniprot
P45984-2 (MAPK9) Y185 Uniprot
Q05397 (PTK2) Y576 Uniprot
Q05397 (PTK2) Y577 Uniprot
Q05397 (PTK2) Y861 Uniprot
Q05397 (PTK2) Y925 Uniprot
Q16539 (MAPK14) T180 Uniprot
Q16539 (MAPK14) Y182 Uniprot
Q658W2 (DKFZp666O0110) Y598 Uniprot
Q658W2 (DKFZp666O0110) Y599 Uniprot
Q8N4X5 (AFAP1L2) Y54 Uniprot
Q99704 (DOK1) Y398 Uniprot

Research Backgrounds


Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL.


Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015 and Tyr-1062.

Proteolytically cleaved by caspase-3. The soluble RET kinase fragment is able to induce cell death. The extracellular cell-membrane anchored RET cadherin fragment accelerates cell adhesion in sympathetic neurons.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein. Endosome membrane>Single-pass type I membrane protein.
Note: Predominantly located on the plasma membrane. In the presence of SORL1 and GFRA1, directed to endosomes.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Phosphorylated form interacts with the PBT domain of DOK2, DOK4 and DOK5 (By similarity). The phosphorylated form interacts with PLCG1 and GRB7 (By similarity). Interacts (not phosphorylated) with PTK2/FAK1 (via FERM domain). Extracellular cell-membrane anchored RET cadherin fragments form complex in neurons with reduced trophic status, preferentially at the contact sites between somas. Interacts with AIP in the pituitary gland; this interaction prevents the formation of the AIP-survivin complex. Binds to ARTN (By similarity). Interacts (inactive) with CBLC and CD2AP; dissociates upon activation by GDNF which increases CBLC:CD2AP interaction. Interacts (via the extracellular domain) with GFRAL (via the extracellular domain); the interaction mediates cellular signaling upon interaction of GFRAL with its ligand GDF15. Interaction with GFRAL requires previous GDF15-binding to GFRAL. Interacts with GFRA1; in the presence of SORL1, the GFRA1/RET complex is targeted to endosomes. Interacts with GDNF.


Belongs to the protein kinase superfamily. Tyr protein kinase family.

Research Fields

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)


1). Growth differentiation factor-15 overexpression promotes cell proliferation and predicts poor prognosis in cerebral lower-grade gliomas correlated with hypoxia and glycolysis signature. Life Sciences, 2022 (PubMed: 35588865) [IF=6.1]

2). CCL2/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages. Frontiers in Oncology, 2019 (PubMed: 31024838) [IF=4.7]

Application: WB    Species: human    Sample: SACC-83 cells

FIGURE 5 | TAMs promoted the proliferation, migration, and invasion of SACC cells via the GDNF/p-RET pathway. The TAMs conditioned media (TAMs-CM) was used to stimulate the SACC-83 cells. The macrophages conditioned media (macrophages-CM) served as the control. The CCR2 antagonist (RS504393, 50 ng/mL),GDNF NAb (2µg/mL), and RET antagonist (PYP-1, 5µM) were used. (A–C) The expression of p-RET and RET in SACC-83 cells were evaluated by western blot.

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.